ALT250117P30000
- 23.40
- 0.000.00%
Altimmune Newsroom
Allurion Stock Soars 70% on Weight-loss Therapy Update
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Jefferies Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $28
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
Promising Prospects for Altimmune: Buy Rating Backed by Upcoming Data Readout and Strategic Expansion
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Stifel Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $18
Altimmune Analyst Ratings
Stifel Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $18
Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy's Buy Rating on Altimmune's Pemvidutide
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Institutional Owners May Consider Drastic Measures as Altimmune, Inc.'s (NASDAQ:ALT) Recent US$56m Drop Adds to Long-term Losses
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Jim Cramer on Altimmune, Inc. (ALT): 'Healthcare Is So Out Of Fashion'
Most Shorted Stocks on Wall Street Heading Into 2025: BYND, KSS, GRPN, and More
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)